ZYUS Life Sciences Corporation
ZLSCF
$0.60
-$0.06-9.09%
| Weiss Ratings | ZLSCF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Rating | ||||
| Reward Index | Very Weak | |||
| Risk Index | Weak | |||
| Risk Grade | D | |||
| Reward Grade | E | |||
| Rating Factors | ZLSCF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Dividend Index | -- | |||
| Growth Index | Fair | |||
| Efficiency Index | Very Weak | |||
| Solvency Index | Fair | |||
| Total Return Index | Weak | |||
| Volatility Index | Weak | |||
| Beta / Standard Deviation | ZLSCF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Beta | -- | |||
| Price History | ZLSCF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| 7-Day Total Return | 0.00% | |||
| 30-Day Total Return | -9.09% | |||
| 60-Day Total Return | -7.69% | |||
| 90-Day Total Return | -7.76% | |||
| Year to Date Total Return | -14.29% | |||
| 1-Year Total Return | -25.93% | |||
| 2-Year Total Return | -- | |||
| 3-Year Total Return | -- | |||
| 5-Year Total Return | -- | |||
| 52-Week High % Change | -25.93% | |||
| 52-Week Low % Change | 0.00% | |||
| Price | ZLSCF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| 52-Week High Price | $0.81 | |||
| 52-Week Low Price | $0.60 | |||
| 52-Week Low Price (Date) | Feb 19, 2025 | |||
| 52-Week High Price (Date) | Apr 03, 2024 | |||
| Valuation | ZLSCF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Market Cap | 37.74M | |||
| Enterprise Value | 43.02M | |||
| Price/Earnings (TTM) | -- | |||
| Earnings Per Share (TTM) | -0.39 | |||
| Earnings Per Share Growth | -3.93% | |||
| Price/Earnings To Growth | -- | |||
| Price/Sales (TTM) | 130.43 | |||
| Price/Book (Q) | 4.05 | |||
| Enterprise Value/Revenue (TTM) | 149.78 | |||
| Price | $0.60 | |||
| Enterprise Value/EBITDA (TTM) | -4.15 | |||
| Enterprise Value/EBIT | -3.58 | |||
| Market Cap Category | Nano Cap | |||
| Dividends and Shares | ZLSCF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Shares Outstanding | 72.18M | |||
| Dividend Yield | -- | |||
| Div. Per Share (Most Recent) | -- | |||
| Dividend Per Share (TTM) | -- | |||
| Payout Ratio (TTM) | -- | |||
| Dividend Per Share (Most Recent) | -- | |||
| Company Info | ZLSCF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Phone Number | 888 651 9987 | |||
| Address | Unit 204 Saskatoon, SK S7N 4L8 | |||
| Website | www.zyus.com | |||
| Country | Canada | |||
| Year Founded | 2018 | |||
| Profitability | ZLSCF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Operating Margin (TTM) | -4,180.13% | |||
| Profit Margin | -8,083.74% | |||
| Management Effectiveness | ZLSCF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Return on Assets | -22.19% | |||
| Return on Equity | -- | |||
| Income Statement | ZLSCF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Revenue (TTM) | 332.30K | |||
| Total Revenue (TTM) | 332.30K | |||
| Revenue Per Share | $0.01 | |||
| Gross Profit (TTM) | -1.42M | |||
| EBITDA (TTM) | -12.00M | |||
| EBIT (TTM) | -13.89M | |||
| Net Income (TTM) | -26.86M | |||
| Net Income Avl. to Common (TTM) | -26.86M | |||
| Total Revenue Growth (Q YOY) | 22.22% | |||
| Earnings Growth (Q YOY) | 8.11% | |||
| EPS Diluted (TTM) | -0.39 | |||
| EPS Diluted Growth (Q YOY) | 11.16% | |||
| Balance Sheet | ZLSCF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Cash and Short-Term Inv. (Q) | 256.10K | |||
| Cash Per Share (Q) | $0.00 | |||
| Total Current Assets (Q) | 2.58M | |||
| Total Preferred Equity (Q) | -- | |||
| Total Equity (Q) | 11.02M | |||
| Current Ratio (Q) | 0.243 | |||
| Book Value Per Share (Q) | $0.15 | |||
| Total Assets (Q) | 25.15M | |||
| Total Current Liabilities (Q) | 10.58M | |||
| Total Debt (Q) | 5.88M | |||
| Total Liabilities (Q) | 14.13M | |||
| Total Common Equity (Q) | 11.02M | |||
| Cash Flow | ZLSCF - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Cash from Investing (TTM) | -174.40K | |||
| Cash from Financing (TTM) | 476.00K | |||
| Net Change in Cash (TTM) | -5.14M | |||
| Levered Free Cash Flow (TTM) | -2.51M | |||
| Cash from Operations (TTM) | -5.45M | |||
